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Abstract
Cognitive changes in patients undergoing treatment for non-central nervous system (CNS) cancers
have been recognized for several decades, yet the underlying mechanisms are not well understood.
Structural, functional and molecular neuroimaging has the potential to help clarify the neural bases
of these cognitive abnormalities. Structural magnetic resonance imaging (MRI), functional MRI
(fMRI), diffusion tensor imaging (DTI), MR spectroscopy (MRS), and positron emission
tomography (PET) have all been employed in the study of cognitive effects of cancer treatment,
with most studies focusing on breast cancer and changes thought to be induced by chemotherapy.
Articles in this special issue of Brain Imaging and Behavior are devoted to neuroimaging studies
of cognitive changes in patients with non-CNS cancer and include comprehensive critical reviews
and novel research findings. The broad conclusions that can be drawn from past studies and the
present body of new research is that there are structural and functional changes associated with
cancer and various treatments, particularly systemic cytotoxic chemotherapy, although some
cognitive and fMRI studies have identified changes at pre-treatment baseline. Recommendations
to accelerate progress include well-powered multicenter neuroimaging studies, a better
standardized definition of the cognitive phenotype and extension to other cancers. A systems
biology framework incorporating multimodality neuroimaging, genetics and other biomarkers will
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be highly informative regarding individual differences in risk and protective factors and disease-
and treatment-related mechanisms. Studies of interventions targeting cognitive changes are also
needed. These next steps are expected to identify novel protective strategies and facilitate a more
personalized medicine for cancer patients.
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Two decades of research, primarily in the breast cancer patient population, has confirmed an
association between cognitive changes and systemic adjuvant chemotherapy (Ahles, Root, &
Ryan, 2012; McDonald & Saykin, 2011; Nelson & Suls, 2013; Wefel, Witgert, & Meyers,
2008) as confirmed by several meta-analyses (Anderson-Hanley, Sherman, Riggs, Agocha,
& Compas, 2003; Falleti, Sanfilippo, Maruff, Weih, & Phillips, 2005; Hodgson, Hutchinson,
Wilson, & Nettelbeck, 2013; Jansen, Miaskowski, Dodd, & Dowling, 2007; Jim et al., 2012;
Stewart, Bielajew, Collins, Parkinson, & Tomiak, 2006). Early work focused on cytotoxic
chemotherapies and long-term survivor samples, and was followed by prospective studies
that also included examination of hormonal therapies. As investigators began to emphasize
prospective study designs it became clear that some patients with breast cancer had
cognitive abnormalities at pre-treatment baseline (Ahles et al., 2008; Wefel, Lenzi,
Theriault, Davis, & Meyers, 2004), raising a question of neural effects of breast cancer,
other host factors or vulnerabilities that impact the brain, or perhaps shared genetic risk with
neurodevelopmental or neurodegenerative disorders (Ahles & Saykin, 2007). Across
cognitive studies, the specific domains affected have been relatively consistent, and include
memory, executive function, processing speed, and verbal and spatial abilities (Anderson-
Hanley et al., 2003; Falleti et al., 2005; Hodgson et al., 2013; Jansen et al., 2007; Jim et al.,
2012; Stewart et al., 2006). Survival after treatment for early stage breast cancer is high and
long-term quality of life of survivors has been identified as an important issue. Although the
changes may be relatively mild as measured by current psychometric methods, such mild
cognitive dysfunction may have a very significant impact on quality of life. Moderate to
severe cognitive deficits have also been reported. While more pronounced changes are often
associated with more intensive and prolonged treatment regimens, individual differences in
response to treatment are not well understood.
The neural basis of cancer and treatment-induced cognitive changes has been a major
question (Ahles & Saykin, 2007; Saykin, Ahles, & McDonald, 2003; Vodermaier, 2009), as
a better understanding of the mechanism(s) of this dysfunction would facilitate selection of
alternative therapies, development of preventative strategies, and identification of those
patients who may be at elevated risk for cognitive changes. Structural, functional, and
molecular neuroimaging have been used to probe the mechanisms underlying observed
changes after adjuvant breast cancer chemotherapy (Conroy, McDonald, O’Neill, & Saykin,
2012; Holohan, Von Ah, McDonald, & Saykin, 2013). In brief, structural changes detected
include decreased gray matter density and volume on anatomic MRI (Conroy, McDonald,
Smith, et al., 2013; de Ruiter et al., 2012; Hosseini, Koovakkattu, & Kesler, 2012; Inagaki et
al., 2007; Koppelmans, de Ruiter, et al., 2012; McDonald, Conroy, Ahles, West, & Saykin,
2010; McDonald, Conroy, Smith, West, & Saykin, 2013; Saykin et al., 2003) and alteration
in white matter integrity and volume on diffusion tensor imaging (DTI) (de Ruiter et al.,
2012; Deprez et al., 2011; Deprez, Billiet, Sunaert, & Leemans, 2013; Koppelmans, Groot,
et al., 2012). fMRI studies have demonstrated post-treatment changes in brain activation
during memory and executive tasks (Conroy, McDonald, Smith, et al., 2013; de Ruiter et al.,
2011; Ferguson, McDonald, Saykin, & Ahles, 2007; Kesler, Bennett, Mahaffey, & Spiegel,
Saykin et al. Page 2
Brain Imaging Behav. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2009; Kesler, Kent, & O'Hara, 2011; Lopez Zunini et al., 2012; McDonald, Conroy, Ahles,
West, & Saykin, 2012) and in resting brain connectivity pattern (Bruno, Hosseini, & Kesler,
2012). Recent arterial spin labeled MRI perfusion data suggests alterations in cerebral blood
flow (Holohan, Wang, et al., 2013). Further, several fMRI studies have detected
abnormalities prior to treatment (Cimprich et al., 2010; McDonald et al., 2012; Scherling,
Collins, Mackenzie, Bielajew, & Smith, 2011, 2012), suggesting a possible substrate for
baseline neuropsychological findings observed in some prospective cognitive studies (Ahles
et al., 2008; Wefel et al., 2004). PET has also been used to characterize metabolic and
cerebral blood flow abnormalities after cancer treatment (Silverman et al., 2007) including
post-treatment depression (Kim, Hwang, Jon, Ham, & Seok, 2008).
Accumulating evidence indicates there are individual differences in risk for cognitive and
brain abnormalities associated with non-CNS cancer and its treatment. An important
challenge is determining the sources for these differences in risk for cognitive decline (Ahles
& Saykin, 2007; McAllister et al., 2004). Limited early data suggest genetic factors are
contributory (Ahles et al., 2003; Small et al., 2011). In addition, baseline differences,
comorbidities, and psychosocial factors among other variables may play a role. Patient age
is likely to be a major factor (Mandelblatt et al., 2013, in press) that has not been well-
studied, as most research has focused on middle-aged women. Older patients, including
men, are increasingly undergoing cytotoxic and hormonal chemotherapies, and a better
understanding of the role of age in modulating the impact of cancer and its treatment on
brain structure and function is critical, particularly as patients enter the peak risk period for
age-associated neurodegenerative disorders. Better understanding of risk factors and
predictors of cognitive and neural outcomes of cancer therapy would facilitate clinical risk/
benefit discussions, leading to more personalized medicine as well development of
preventative and rehabilitative interventions. Prior studies in this area, particularly those
focusing on neural mechanisms, have had relatively small sample sizes, limiting the ability
to examine risk and predictive factors.
Papers in this Special Issue
The series of articles begins with several comprehensive and critical reviews of the use of
advanced neuroimaging techniques to study the neural bases of cognitive changes in non-
CNS cancers and cancer therapeutics. Most of the existing studies have been completed in
patients undergoing treatment for breast cancer and these studies are therefore emphasized.
With the high rate of survival in early stage breast cancer, cognitive problems after systemic
treatment and their impact on quality of life has been a growing concern. Studies remain to
be completed in most other forms of non-CNS cancer, and the present reviews and original
research reports mostly but not exclusively concentrate on breast cancer and its treatment.
Reviews
The earliest studies employed quantitative analyses of structural MRI. McDonald and
Saykin (2013) review the range of structural MRI studies, including post-chemotherapy
breast cancer survivor study designs as well as the more limited number of recent
prospective studies. Methodological considerations are discussed including manual vs.
automated analytic approaches to quantify gray and white matter tissue properties and the
issue of control or contrast groups included in these studies. Structural MRI studies, as
reviewed by these authors, demonstrate lower gray and white matter volume and density
after systemic cytotoxic chemotherapy with the most consistent findings shown in the
frontal and temporal lobe regions. Much less information is available regarding other
therapeutic modalities such as anti-estrogen hormonal treatment, but initial evidence
suggests a potential contribution to structural changes on imaging. Some studies have shown
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a relationship between structural imaging and cognitive changes as well as other biological
markers.
Diffusion tensor imaging (DTI) is another important structural MRI-based tool for assessing
neuroanatomical changes in non-CNS cancer, particularly for detection of microstructural
alterations in white matter. Deprez et al. (2013) provide a detailed review of the
fundamentals of DTI methodology and its application to studies of chemotherapy-induced
cognitive impairment. Paralleling results employing conventional structural MRI, cross-
sectional and longitudinal DTI studies have shown abnormal microstructure in white matter
regions important for cognition. DTI results have also been found to correlate with cognitive
performance, suggesting a functional connection between reduced "white matter integrity"
and cognitive changes after chemotherapy.
Moving beyond brain structure, fMRI has the potential to detect alterations in the neural
circuitry and networks subserving cognitive functioning after systemic treatment in cancer
patients. De Ruiter and Schagen (2013) provide a detailed analysis of the fMRI studies
(n=14) of systemic treatment for non-CNS cancers published to date. Long-term breast
cancer survivors (5–10 years since therapy) treated with chemotherapy have been compared
to other cancer contrast groups and controls in cross-sectional fMRI studies. Studies
employing executive function probe tasks have demonstrated prefrontal and parietal
hypoactivation whereas fMRI studies of episodic memory have similarly shown
hypoactivation during encoding but differ in demonstrating hyperactivation during memory
retrieval. The authors discuss the interpretation of these alterations, including reduction of
neural function in brain regions that support cognition as a result of chemotherapy and the
concept of compensatory hyperactivation to support adequate memory retrieval. The few
available prospective fMRI studies of executive functioning and episodic memory show a
more complex pattern of hypo- and hyperactivation that may be related to the closer
temporal proximity to systemic treatment or other mechanisms. de Ruiter and Schagen also
discuss the data emerging in fMRI studies of patients being treated for prostate cancer which
show preliminary evidence for decreased activity after androgen deprivation therapy. These
authors conclude by discussing multiple testing, sample size and power considerations,
among other methodological issues for fMRI studies.
Pomykala et al. (2013) review recent imaging studies of cancer- and chemotherapy-related
cognitive changes focusing on a comparison of findings across modalities (various MRI and
PET techniques) in studies of changes in brain structure and function associated with
chemotherapy. The authors emphasize the similar changes in brain activation in parietal
regions identified by functional PET (Silverman et al., 2007) and fMRI (de Ruiter et al.,
2011) studies in survivors 5–10 years after systemic chemotherapy. Similarly cross-sectional
[O15]PET findings in frontal cortex (Silverman et al., 2007) were noted to be similar to
prospectively assessed changes in frontal gray matter density one month after chemotherapy
(McDonald et al., 2010).
Another window to the neural bases of cognitive changes associated with cancer and
systemic therapy is preclinical studies employing small animal models of chemotherapy
neurotoxicity. Seigers and colleagues (2013) review recent advances from animal studies
highlighting the role of the blood-brain barrier in cognitive impairment and issues related to
the development of neuroprotective strategies. Although human imaging studies can provide
important longitudinal structural, functional and molecular information, small animal
models have the advantage of permitting detailed histological analysis on a microscopic
level to more fully characterize the biological significance of any findings. Seigers et al.
summarize research studies that examined implicated biological processes including
apoptosis, vascular supply, CSF composition, electrophysiology, histone acetylation,
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inflammation, morphology, neurogenesis/gliogenesis, neurotransmitter/monoamine release
and oxidative stress. Given the ability of animal studies to address these fundamental
mechanisms, preclinical methods are highly complementary with human neuroimaging. In
the future, prospective small animal neuroimaging studies are likely to provide even better
integration of preclinical and clinical research.
New Research Findings
Neuroimaging data using various samples, techniques and study designs is accruing at a
rapid pace, as reflected by the reports of novel findings in this special issue. Lopez Zunini
and colleagues (2012) used fMRI to investigate verbal memory recall in breast cancer
patients receiving chemotherapy and controls in a prospective design, and report on
differences at baseline as well as changes one month after chemotherapy. Their paper
describes reduced activation in the anterior cingulate in patients on baseline fMRI scans
compared to controls during memory retrieval. Patients treated with chemotherapy also
showed decreased activation in several regions (bilateral insula, the left inferior orbitofrontal
cortex and the left middle temporal gyrus) as well as less activation compared to controls in
several frontal and temporal regions. A notable feature of the Lopez Zunini study is the
careful attention to potential confounding factors such as depression, anxiety, and fatigue,
which accounted for some of the observed changes in activation patterns.
Dumas and colleagues (2013), also using fMRI to prospectively study patients being treated
for breast cancer, analyzed functional connectivity to examine neural processes underlying
the reported executive and attentional deficits observed in cognitive studies. Measures of
functional connectivity can be extracted from a task-free or resting state fMRI or from task-
based paradigms, as in the present study. Functional connectivity analyses typically employ
a seed-based approach or independent components analysis (ICA) to determine the
interconnectivity of brain regions based on their temporal correlation. The report by Dumas
et al. describes the results of a small study employing a seed-based analysis of task related
fMRI using a 3-back task, similar to that employed in prior studies (McDonald et al., 2012),
in nine women who were scanned before and one month and one year after chemotherapy.
To examine connectivity changes, the dorsal anterior attention network was targeted by
placing a seed in the intraparietal sulcus (IPS), whereas the default mode network was
targeted by a seed in the posterior cingulate cortex (PCC). Dumas et al. report a reduction of
functional connectivity a month after chemotherapy with partial return to baseline on one
year follow-up. The authors also described an increase in subjective memory complaints,
although this was not directly analyzed in relation to connectivity changes. Results of this
small and uncontrolled prospective pilot study are intriguing and consistent with other
reports suggesting that there may be altered brain connectivity after chemotherapy (Bruno et
al., 2012; Hosseini et al., 2012).
MRS provides another window into cerebral function, in this case at the level of
neurochemistry. Kesler and colleagues (2013), studying breast cancer patients, compared
proton (1H) MRS metabolites and metabolite ratios in 19 survivors treated with
chemotherapy to those in 17 controls. The authors describe novel results including increased
prefrontal levels of the myo-inositol (MI) and choline (Cho) metabolites and decreased N-
acetylaspartate (NAA)/Cho and NAA/mI ratios in the breast cancer group. Of note, the
Kesler group found a relationship in both groups between subjective memory functioning
and metabolite levels.
The papers by Lopez Zunini et al., Dumas et al. and Kesler et al. in this issue demonstrate
the complementary nature of task-based fMRI, functional connectivity and metabolic signals
in demonstrating changes in patients who have undergone chemotherapy. Numerous
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hypotheses have been proposed for cancer and chemotherapy-induced changes in cerebral
function (e.g., Ahles & Saykin, 2007) and one of the most obvious and important biological
alterations relates to altered neuroendocrine function.
In this issue, Conroy and colleagues (2013) report prospective fMRI changes in breast
cancer patients focused on the issue of chemotherapy-induced amenorrhea (CIA), a common
occurrence in pre- and peri-menopausal patients. Data from the 3-back working memory
task (McDonald et al., 2012) collected at pre-treatment baseline and one month after
chemotherapy was used to compare changes in brain activation and deactivation patterns in
patients who underwent CIA to those who were post-menopausal, as well as to pre- and
post-menopausal healthy controls. The authors describe increased pre- to post-chemotherapy
fMRI activation that was specific to the CIA group, which was also strongly correlated with
change in processing speed on neuropsychological testing, suggesting this increase in brain
activity reflects effective compensatory processes. An important aspect of this study is the
finding that the pattern of change in brain activity from pre- to post-chemotherapy varies
according to pre-treatment menopausal status, which has potential implications for risk
appraisal and development of prevention or treatment strategies for cognitive changes in
CIA.
Researchers are just beginning to integrate blood-based biomarkers and neuroimaging in
studies of cancer and cognition. Silverman and colleagues (Pomykala, Ganz, et al., 2013)
examined relationships between circulating proinflammatory cytokines (IL-1ra, sTNF-RII,
CRP, and IL-6), regional cerebral metabolism on FDG PET, and cognitive complaints in 33
early stage breast cancer patients (23 treated with chemotherapy) at baseline and one year
after adjuvant chemotherapy. At baseline, left medial frontal and right inferior lateral
anterior temporal cortices were correlated with inflammatory markers within the
chemotherapy group only. On one year follow-up, there were persisting correlations in the
medial frontal cortex and the temporal cortex with some spatial shifting. Memory
complaints were associated with metabolism on PET and cytokine analyte levels in
chemotherapy-treated patients. This is an important inroad building on limited prior work
correlating cognitive changes and proinflammatory cytokine levels (Ganz et al., 2013;
Kesler, Janelsins, et al., 2013; Kesler, Watson, et al., 2013; Myers, 2010; Walker, Drew,
Antoon, Kalueff, & Beckman, 2012).
Neuroimaging can be used to investigate many aspects of cancer and cognition as well as
other related survivorship issues. In a novel study, Versace and colleagues used fMRI to
investigate the basis of the loss of sexual desire and arousability often reported by breast
cancer survivors (Versace et al., 2013). Neural responses to erotic and other emotional
stimuli in survivors with and without distress were studied to test the hypothesis that cancer
or treatment for cancer damages brain reward circuitry. The authors found that women who
were distressed about their desire had reduced brain responses to erotica in reward-
associated regions including the anterior cingulate and dorsolateral prefrontal cortex. Further
work will be needed to determine if this is related to chemotherapy, hormone therapy, and/or
menopausal status.
High dose conditioning regimens for cancer patients requiring hematopoietic stem cell
transplantation (HSCT) for hematologic cancers have received little prior study. Correa et al.
report prospective structural neuroimaging and cognitive data in adult stem cell transplant
recipients (Correa et al., 2013). These authors examined regional gray matter and ventricular
volumes and cognitive function before and one year after HSCT in 28 patients and 10
healthy controls. Patients showed evidence of reduced gray matter volume in the middle
frontal gyrus bilaterally and in the left caudate nucleus, as well as a significant increase in
left lateral ventricle volume and in total ventricle volume in the patient group relative to
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healthy controls. This is important in identifying changes in a particularly high risk group
for cognitive impairment associated with treatment.
Another important application of neuroimaging and related tools is to serve as biomarkers to
monitor the effects of cognitive interventions for cancer patients. Ercoli and colleagues
examined the feasibility of a cognitive rehabilitation program in breast cancer survivors who
had persisting cognitive complaints 18 months to five years after treatment (Ercoli et al.,
2013). The intervention included once-weekly group cognitive training for five weeks.
Multiple outcome measures and follow-up time points were included. These authors
reported significant reductions in total and memory-specific cognitive complaints from pre-
intervention to post-intervention that were maintained at four months post-intervention. In a
small but novel substudy, eight of the participants were evaluated prospectively with
quantitative resting state electroencephalography (qEEG). Absolute alpha power over the
course of the intervention was associated with reduced complaints at several outcome
intervals, suggesting that qEEG may serve as a potential biomarker for improvement in self-
reported complaints.
Recommendations to Advance Research on Cancer- and Cancer
Treatment-Associated Cognitive Dysfunction
Much has been learned from past studies including the new work included in this special
issue of Brain Imaging and Behavior. In the final section, the special issue editors outline a
series of recommendations based on work to date in cancer and other fields that has
implications for moving research on cancer and cognition to the next level. Although it will
not be appropriate or feasible to incorporate all of the following methods or design features
in any particular study, these suggestions are offered to stimulate broader and more powerful
approaches to the problems of cancer- and cancer treatment-associated neurocognitive
dysfunction. In particular, we believe that many key gaps in current knowledge could be
addressed by larger-scale multicenter studies that include refined phenotypes paired with
advanced neuroimaging, genetics and biomarkers.
Refined Cognitive Phenotype Definitions Are Needed
1 Cognitive assessment should include reliable psychometric tests with good
sensitivity and specificity that cover key domains reviewed above with
established relevance to cancer and cancer treatment (e.g., executive function,
processing speed, working memory, episodic memory, verbal and spatial
abilities). No specific tests have been conclusively demonstrated to outperform
others but there is good evidence to support the relevant domains. Inclusion of
some computer-based tests assessing response times might be considered.
Attention to ecological validity in terms of impact of measured domains on
activities of daily living is another important consideration. These concepts are
generally consistent with prior consensus group recommendations for studies of
cancer and cognition (Tannock, Ahles, Ganz, & Van Dam, 2004; Wefel, Vardy,
Ahles, & Schagen, 2011).
2 Ratings of cognitive concerns should be included, such as subjective and
informant/study partner/clinician-based perception, as in some cases these may
be among the earliest and most sensitive indicators of alterations in cognition.
An emergent model from the MCI/prodromal Alzheimer’s disease research field
is defining subjective cognitive decline (SCD) based on self-perception.
Individuals whose self-perceived concerns are validated by a family member,
friend, co-worker or clinician, or who have other risk factors for cognitive
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decline are classified as “SCD-plus” and have been found to be more likely to
demonstrate positive findings on imaging and other biomarkers. In general,
careful tracking of subjective and informant concerns or “complaints” is
consistent with the patient reported outcomes (PRO) model widely applied to
cancer research. Ascertainment of informant ratings has been underrepresented
in cognitive research on cancer and chemotherapy effects but should be
relatively easy to add. This can be expected to provide potentially important
complementary information to subjective changes and psychometric data.
3 Standardized definition of abnormal performance. For comparison across
studies, whether observational or clinical trials, some standardization or
harmonization of classification is important. Cut-off scores between low normal
and impaired psychometric performance, although arbitrary, are often employed
in research studies of cognitive dysfunction, driven by the perceived need for a
standard metric to define binary classification of subjects into impaired and
unimpaired categories. The criteria for defining cutoffs for cognitive scores is a
challenging area in the absence of a clear outcome such as measureable disease
progression used in other contexts. In the definition of mild cognitive
impairment (MCI) occurring in prodromal Alzheimer’s disease, scores of 1.5
standard deviations (SD) or more below normal age, education and gender
adjusted performance is considered abnormal. In some cases scores 1.0 SD
below are considered sensitive to early changes as in work on early amnestic
MCI (Risacher et al., 2013), but that greater sensitivity is purchased at the price
of lower specificity. Many investigators consider the presence of deficits to
ultimately be a clinical decision based on all available information. An
alternative basis for achieving binary classification for the sake of defining
inclusion criteria or outcomes for research studies is to compare an individual's
cognitive performance not to population norms in the manner delineated above
for defining MCI, but relative to that individual's own normal level of cognitive
performance, and to a degree greater or faster than would be expected for
normal aging (Silverman, Mosconi, Ercoli, Chen, & Small, 2008). In
prospective cancer treatment studies this can be accomplished by including
baseline psychometric data. In post-treatment studies investigators should
attempt to include a more accurate analysis of baseline abilities based on
continuing educational achievement, occupation and professional and social
activities over time. Self- and informant-based ratings of cognitive concern or
complaints can also be potentially classified using standardized cut-offs but the
same caveat applies in terms of decline being assessed relative to the
individual’s own baseline. It is also important to keep in mind that some studies
ask only 1–2 questions whereas other employ detailed scales with a large
number of items.
4 The role of psychosocial factors deserves more attention, including more
sophisticated conceptual models of the interaction of social, self-regulatory and
biological factors (Arndt et al., 2013). Social networks, studied with regard to
cancer survival (Kroenke, Kubzansky, Schernhammer, Holmes, & Kawachi,
2006), could also be analyzed for bidirectional relationships with cognitive
function.
5 DSM-5, the recently released edition of the Diagnostic and Statistical Manual
(American Psychiatric Association, 2013) includes the categories of mild and
major neurocognitive disorder. Cognitive changes associated with non-CNS
cancer and chemotherapy-associated cognitive changes are likely to fall under
the DSM-5 mild neurocognitive disorder framework, although in some cases
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more pronounced changes would meet criteria for major neurocognitive
disorder. In either case it would be important to record which DSM-5 criteria are
met for harmonization across future studies.
Sample Composition
6 The majority of neuroimaging studies to date have included patients undergoing
treatment for breast cancer. Future brain imaging studies are needed to address
changes in brain structure and function associated with other non-CNS cancers.
7 Extension to broader age and education ranges and more demographically
diverse samples. The role of age, hypothesized accelerated aging, and
interactions with aging processes has been discussed but under-investigated.
Similarly, the role of education, occupation and other factors related to cognitive
reserve warrant further attention as potential moderators of cognitive outcomes.
More attention to socioeconomic, racial/ethnic and language-related factors
would also be useful to extend the generalizability of findings in future research.
Study Design, Scanning and Sample Collection
8 Prospective neuroimaging studies are needed. Most research to date has focused
on survivor cohorts with the follow-up intervals ranging from one year to
several decades. Inclusion of baseline scans prior to systemic treatment with
cytotoxic chemotherapy or hormonal therapy is highly desirable despite the
challenges in obtaining these data. Where feasible, baseline scanning followed
by early post-treatment imaging (e.g., within the first 1–6 months after
treatment) with subsequent longer term follow-up scans a year or more after the
conclusion of treatment are recommended. Limited existing data reviewed above
suggest acute effects on brain structure and function with partial recovery by one
year, as well as residual changes observed in the long-term survivor studies.
Ultimately, the issue of optimal time points for neuroimaging studies warrants
further investigation.
9 Large well-powered, multicenter neuroimaging studies are needed in research on
cancer and cognition. Most neuroimaging studies to date have modest sample
sizes. When considering the relationships to cognitive performance, biomarkers
and especially potential genetic moderators of cognitive outcome, imaging
studies will need to be quite large to have sufficient power to detect the
influence of these factors after controlling for multiple testing. A parallel to
studies of Alzheimer’s disease and MCI is informative. Early MRI and PET
studies typically included relatively small samples. In 2004, the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) was launched across 59 sites in the US
and Canada with standardized clinical, cognitive, structural MRI, genetics and
biofluid data collection, with FDG PET and later amyloid PET scans obtained in
a subsample. In ADNI-2 all participants undergo the detailed MRI, FDG and
amyloid PET, genetics, CSF and blood biomarker studies. This large data set
made publicly available to the scientific community has resulted in nearly 400
publications to date (Weiner et al., 2013), reflecting the power of comprehensive
“big data” sets to drive research. ADNI included genome-wide association study
(GWAS) genotype data (Saykin et al., 2010) and recently whole genome
sequencing data has been added. The combination of genetic data (APOE or
GWAS) with imaging and other phenotypes led to over 100 publications by the
end of 2012 (Shen et al., 2013). This open, collaborative, and highly productive
paradigm can provide a model for advancement of research into the cognitive
and neural effects of cancer and cancer treatment.
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10 Standardization of MRI and PET methods has been demonstrated by ADNI and
other large scale multicenter studies. For studies of cognition changes associated
with cancer and cancer treatment, a common core of scan sequences should be
developed to facilitate cross-study comparison and potentially inclusion in a
large multicenter study. MRI and PET methods have been standardized across
the major vendor platforms and models (i.e., GE, Philips and Siemens scanners).
At present, a minimal approach would be inclusion of a high resolution 3D
volumetric MRI such as the T1-weighted MPRAGE sequence used in ADNI
(for detailed protocols for ADNI-1 and ADNI-2 see: http://adni.loni.usc.edu/
methods/documents/mri-protocols/). Similarly, for assessment of white matter
hyperintensities and other age associated microvascular changes, a 3D FLAIR
sequence might be included. Recent studies described in this special issue and
elsewhere suggest that several advanced MRI techniques may be particularly
sensitive to cancer- and treatment-associated changes. These include diffusion
imaging (e.g., DTI and DSI), resting state (task free) fMRI, memory and
executive task-based fMRI, MRS and arterial spin labeled perfusion. Employing
these techniques across sites in a multicenter framework is more challenging,
although each has been used in such studies spanning different scanners and
software platforms. Multimodality imaging across MRI techniques, and
potentially also including PET studies, is likely to be particularly informative for
differentiating treatment and disease mechanisms.
11 Special imaging databases, processing pipelines and analytic techniques are also
needed for standardization or harmonization in multicenter studies. There is
ample proof of concept that these methods are effective in multicenter studies of
other disorders, suggesting that they can be applied in future cancer studies.
High throughput automated analyses of structure and function will be needed
and are available, as are meta-analytic approaches for imaging data. A
particularly promising area includes analyses of alteration of the structural and
functional “connectome” (Sporns, 2013a, 2013b; Sporns, Tononi, & Kotter,
2005) or network properties of the brain after cancer treatment (Dumas et al.,
2013; Hosseini et al., 2012).
12 There is a paucity of PET studies addressing the cognitive effects of cancer and
cancer treatment. Although PET requires minor exposure to ionizing radiation
this technique has the distinct advantage of permitting specific molecular
targeting. Many of the candidate mechanisms for cancer-associated cognitive
dysfunction (Ahles & Saykin, 2007; Saykin et al., 2003) such as alterations in
inflammation/immune activation, vascular function and growth factors, efflux
transporters, hormones, neurotransmitters and receptors, proliferation/
neurogenesis, DNA damage/repair and plasticity markers, as well as abnormal
proteins could all be potentially studied using targeted molecular imaging.
Although a powerful tool, a limitation of PET is that only one molecular target
can be assessed at a time, so that a limited number of hypotheses can be tested in
a given study. Once there is a strong hypothesis PET could be used in a targeted
manner to pursue a particular mechanism.
13 Standardized clinical/cognitive, genetic and biomarker collection approaches are
well established for large scale studies and could readily be included along with
neuroimaging for studies of cancer and cognition. Biorepository banking of
blood samples for DNA, RNA, plasma and serum could greatly enhance studies
of cancer and cognition. Recent analyses of proinflammatory cytokines
(Pomykala, Ganz, et al., 2013) and DNA damage markers (Conroy, McDonald,
Smith, et al., 2013) from blood samples are already proving informative.
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Proteomics analyses can be used to study many analytes in blood plasma or
serum or CSF when available. Analytes related to relevant biological pathways
can be measured prospectively including endocrine, immune, oxidative stress,
growth factors, apoptosis, and many other pathways. Many other assays such as
analysis of telomere length and accelerated aging effects in relation to imaging
data become possible if DNA samples are banked and available. Similarly, a
range of other host factors can be studied including variation in candidate genes
for cognition, genes from targeted biological pathways, and ultimately GWAS
and whole genome or exome sequencing for less common variants can be
undertaken. RNA sequencing or expression profiling from accessible peripheral
blood may be revealing as a marker for dynamic changes in the transcriptome,
and may in part reflect transcriptional changes in brain given conservation of
gene expression. MicroRNAs, small RNAs that are important regulators of
transcription, play a significant role in cancer and neurodegenerative disorders
such as AD (Holohan, Lahiri, Schneider, Foroud, & Saykin, 2012). Finally, the
gut-brain relationship is receiving increasing attention in cancer and
neurodegeneration research and assays of the microbiome are likely to prove
informative if samples are banked.
Intervention Studies
14 Therapeutic and preventative strategies targeting cognitive changes in cancer
patients, including pharmacological as well as behavioral/psychosocial
interventions such as cognitive rehabilitation, exercise, diet and other lifestyle
factors, could all be studied with the neuroimaging and other biomarker methods
discussed above, to examine the impact on physiological processes and
mechanisms.
Ethical, Legal and Social Issues
15 Ethical, legal and social issues (ELSI) will need to be addressed. Investigators
will need to consider what participants should be told about results of imaging,
genetics and other biomarker studies designed to address cognitive risks and
changes, if anything. The methods discussed above are largely experimental at
present, but in the future at least some are very likely to prove to be predictive
and become part of personalized cancer medicine, including diagnostic,
prognostic and therapeutic aspects. ELSI research is needed to better understand
the implications of returning or not returning such results to research
participants.
16 Another important ELSI relates to informed consent with regard to data sharing.
There is increased recognition that data sharing greatly facilitates scientific
research. The NIH mandates data sharing plans for larger studies and for all
GWAS and a similar plan for required biorepository deposition is being
developed for genome sequencing studies. ADNI, discussed above as an
example of open and collaborative science, makes all data available to qualified
investigators around the world with a low barrier for obtaining data, and this has
proven to be extremely productive in facilitating progress. Yet making genomic,
imaging and other potentially identifiable data broadly available is not without
some degree of risk. Involvement of ELSI experts will be important to help the
field appropriately manage risks, provide appropriate informed consent, and
address national and international data sharing.
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Conclusions
We hope that readers will enjoy the thorough reviews of existing neuroimaging research on
cancer and cancer treatment as well as the novel findings reported in this special issue of
Brain Imaging and Behavior. In addition, we hope that investigators will find the above
recommendations useful for advancing neuroimaging research on cancer and cognition as
part of a comprehensive systems biology framework.
Acknowledgments
The authors wish to thank the Organizing Committee of the International Cognition and Cancer Task Force
(ICCTF; http://www.icctf.com/). This project and special issue are an outgrowth of the Neuroimaging Working
Group of the ICCTF. The authors gratefully acknowledge support from the following funding sources. Drs. Saykin
and McDonald: Supported in part by the National Cancer Institute (R01 CA101318, P30 CA082709 and R25
CA117865), the National Institute on Aging (R01 AG19771, P30 AG10133), and the National Library of Medicine
(R01 LM011360). Dr. de Ruiter: Grant numbers KWF 2009–4284; KWF 2010–4894; KWF 2012–5495. Dr.
Deprez: The Fonds Wetenschappelijk Onderzoek–Vlaanderen (Grant No. G.048010N) and by the Stichting tegen
Kanker. Dr. Silverman: National Institute of Neurological Diseases and Stroke (R21 NS071385).
References
Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on
the state of the science. J Clin Oncol. 2012; 30(30):3675–3686. [PubMed: 23008308]
Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev
Cancer. 2007; 7(3):192–201. [PubMed: 17318212]
Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, Kaufman PA.
Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat.
2008; 110(1):143–152. [PubMed: 17674194]
Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, Mott LA. The relationship of
APOE genotype to neuropsychological performance in long-term cancer survivors treated with
standard dose chemotherapy. Psychooncology. 2003; 12(6):612–619. [PubMed: 12923801]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
2013
Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of
treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol
Soc. 2003; 9(7):967–982. [PubMed: 14738279]
Arndt J, Das E, Schagen SB, Reid-Arndt SA, Cameron LD, Ahles TA. Broadening the cancer and
cognition landscape: the role of self-regulatory challenges. Psychooncology. 2013
Bruno J, Hosseini SM, Kesler S. Altered resting state functional brain network topology in
chemotherapy-treated breast cancer survivors. Neurobiol Dis. 2012; 48(3):329–338. [PubMed:
22820143]
Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Welsh RC.
Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp
Neuropsychol. 2010; 32(3):324–331. [PubMed: 19642048]
Conroy SK, McDonald BC, Ahles TA, West JD, Saykin AJ. Chemotherapy-induced amenorrhea: a
prospective study of brain activation changes and neurocognitive correlates. Brain Imaging Behav.
2013
Conroy, SK.; McDonald, BC.; O’Neill, DP.; Saykin, AJ. Neuroimaging in cancer and oncology. In:
Noggle, CA.; Dean, RS., editors. The Neuropsychology of Cancer and Oncology. Springer; 2012.
p. 235-260.
Conroy SK, McDonald BC, Smith DJ, Moser LR, West JD, Kamendulis LM, Saykin AJ. Alterations in
brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and
relation to oxidative DNA damage. Breast Cancer Res Treat. 2013; 137(2):493–502. [PubMed:
23263697]
Saykin et al. Page 12
Brain Imaging Behav. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Correa DD, Root JC, Baser R, Moore D, Peck KK, Lis E, Relkin N. A prospective evaluation of
changes in brain structure and cognitive functions in adult stem cell transplant recipients. Brain
Imaging Behav. 2013
de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, Schagen SB. Late effects of
high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging
results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012; 33(12):2971–2983.
[PubMed: 22095746]
de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FS, Nederveen AJ, Schagen SB.
Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast
cancer. Hum Brain Mapp. 2011; 32(8):1206–1219. [PubMed: 20669165]
de Ruiter MB, Schagen SB. Functional MRI studies in non-CNS cancers. Brain Imaging Behav.
2013:1–21. [PubMed: 22660945]
Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, Van den Stock J, Sunaert S. Chemotherapy-
induced structural changes in cerebral white matter and its correlation with impaired cognitive
functioning in breast cancer patients. Hum Brain Mapp. 2011; 32(3):480–493. [PubMed:
20725909]
Deprez S, Billiet T, Sunaert S, Leemans A. Diffusion tensor MRI of chemotherapy-induced cognitive
impairment in non-CNS cancer patients: a review. Brain Imaging Behav. 2013
Dumas JA, Makarewicz J, Schaubhut GJ, Devins R, Albert K, Dittus K, Newhouse PA. Chemotherapy
altered brain functional connectivity in women with breast cancer: a pilot study. Brain Imaging
Behav. 2013
Ercoli LM, Castellon SA, Hunter AM, Kwan L, Kahn-Mills BA, Cernin PA, Ganz PA. Assessment of
the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive
complaints. Brain Imaging Behav. 2013:1–11. [PubMed: 22660945]
Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive
impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis
of the current literature. Brain Cogn. 2005; 59(1):60–70. [PubMed: 15975700]
Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in
monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007; 25(25):
3866–3870. [PubMed: 17761972]
Ganz PA, Bower JE, Kwan L, Castellon SA, Silverman DH, Geist C, Cole SW. Does tumor necrosis
factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav
Immun. 2013; 30(Suppl):S99–S108. [PubMed: 22884417]
Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T. A meta-analysis of the effects of
chemotherapy on cognition in patients with cancer. Cancer Treat Rev. 2013; 39(3):297–304.
[PubMed: 23219452]
Holohan KN, Lahiri DK, Schneider BP, Foroud T, Saykin AJ. Functional microRNAs in Alzheimer's
disease and cancer: differential regulation of common mechanisms and pathway. Front Genet.
2012; 3:323. [PubMed: 23335942]
Holohan KN, Von Ah D, McDonald BC, Saykin AJ. Neuroimaging, cancer, and cognition: state of the
knowledge. Semin Oncol Nurs. 2013; 29(4):280–287. [PubMed: 24183159]
Holohan, KN.; Wang, Y.; McDonald, BC.; Conroy, SK.; Smith, DJ.; West, JD.; Saykin, AJ. Cerebral
perfusion and cognition after breast cancer chemotherapy: A prospective PASL MRI study; Paper
presented at the Organization of Human Brain Mapping, OHBM 2013; Seattle, WA. 2013.
Hosseini SM, Koovakkattu D, Kesler SR. Altered small-world properties of gray matter networks in
breast cancer. BMC Neurol. 2012; 12:28. [PubMed: 22632066]
Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, Uchitomi Y. Smaller
regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed
to adjuvant chemotherapy. Cancer. 2007; 109(1):146–156. [PubMed: 17131349]
Jansen CE, Miaskowski CA, Dodd MJ, Dowling GA. A meta-analysis of the sensitivity of various
neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients
with breast cancer. Oncol Nurs Forum. 2007; 34(5):997–1005. [PubMed: 17878128]
Saykin et al. Page 13
Brain Imaging Behav. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, Small BJ. Meta-analysis of cognitive
functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin
Oncol. 2012; 30(29):3578–3587. [PubMed: 22927526]
Kesler SR, Bennett FC, Mahaffey ML, Spiegel D. Regional brain activation during verbal declarative
memory in metastatic breast cancer. Clin Cancer Res. 2009; 15(21):6665–6673. [PubMed:
19843664]
Kesler SR, Janelsins M, Koovakkattu D, Palesh O, Mustian K, Morrow G, Dhabhar FS. Reduced
hippocampal volume and verbal memory performance associated with interleukin-6 and tumor
necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun.
2013; 30(Suppl):S109–S116. [PubMed: 22698992]
Kesler SR, Kent JS, O'Hara R. Prefrontal cortex and executive function impairments in primary breast
cancer. Arch Neurol. 2011; 68(11):1447–1453. [PubMed: 22084128]
Kesler SR, Watson C, Koovakkattu D, Lee C, O'Hara R, Mahaffey ML, Wefel JS. Elevated prefrontal
myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav. 2013
Kim LS, Hwang HS, Jon DI, Ham BJ, Seok JH. Dysfunction of the neural network associated with
sustained attention in cancer patients with clinically significant depressive symptoms. Neurosci
Lett. 2008; 447(1):1–6. [PubMed: 18845225]
Koppelmans V, de Ruiter MB, van der Lijn F, Boogerd W, Seynaeve C, van der Lugt A, Schagen SB.
Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant
chemotherapy. Breast Cancer Res Treat. 2012; 132(3):1099–1106. [PubMed: 22205140]
Koppelmans V, Groot MD, de Ruiter MB, Boogerd W, Seynaeve C, Vernooij MW, Breteler MM.
Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant
chemotherapy. Hum Brain Mapp. 2012
Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I. Social networks, social
support, and survival after breast cancer diagnosis. J Clin Oncol. 2006; 24(7):1105–1111.
[PubMed: 16505430]
Lopez Zunini RA, Scherling C, Wallis N, Collins B, Mackenzie J, Bielajew C, Smith AM. Differences
in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a
prospective fMRI study. Brain Imaging Behav. 2012
Mandelblatt JS, Hurria A, McDonald BC, Saykin AJ, Stern RA, VanMeter JW. For the TLC Study
(Thinking and Living with Cancer). Cognitive effects of cancer and its treatments at the
intersection of aging: What do we know; What do we need to know? Seminars in Oncology. 2013
(in press).
McAllister TW, Ahles TA, Saykin AJ, Ferguson RJ, McDonald BC, Lewis LD, Rhodes CH. Cognitive
effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. Curr
Psychiatry Rep. 2004; 6(5):364–371. [PubMed: 15355759]
McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Gray matter reduction associated with
systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat.
2010; 123(3):819–828. [PubMed: 20690040]
McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Alterations in brain activation during
working memory processing associated with breast cancer and treatment: a prospective functional
magnetic resonance imaging study. J Clin Oncol. 2012; 30(20):2500–2508. [PubMed: 22665542]
McDonald BC, Conroy SK, Smith DJ, West JD, Saykin AJ. Frontal gray matter reduction after breast
cancer chemotherapy and association with executive symptoms: a replication and extension study.
Brain Behav Immun. 2013; 30(Suppl):S117–S125. [PubMed: 22613170]
McDonald BC, Saykin AJ. Neurocognitive dimensions of breast cancer and its treatment.
Neuropsychopharmacology. 2011; 36(1):355–356. [PubMed: 21116248]
McDonald BC, Saykin AJ. Alterations in brain structure related to breast cancer and its treatment:
chemotherapy and other considerations. Brain Imaging Behav. 2013:1–14. [PubMed: 22660945]
Myers JS. The possible role of cytokines in chemotherapy-induced cognitive deficits. Adv Exp Med
Biol. 2010; 678:119–123. [PubMed: 20738013]
Nelson WL, Suls J. New approaches to understand cognitive changes associated with chemotherapy
for non-central nervous system tumors. J Pain Symptom Manage. 2013; 46(5):707–721. [PubMed:
23522517]
Saykin et al. Page 14
Brain Imaging Behav. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Pomykala KL, de Ruiter MB, Deprez S, McDonald BC, Silverman DH. Integrating imaging findings
in evaluating the post-chemotherapy brain. Brain Imaging Behav. 2013
Pomykala KL, Ganz PA, Bower JE, Kwan L, Castellon SA, Mallam S, Silverman DH. The association
between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints
following adjuvant chemotherapy for breast cancer. Brain Imaging Behav. 2013
Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, Saykin AJ. Alzheimer's Disease
Neuroimaging Initiative. The role of apolipoprotein E (APOE) genotype in early mild cognitive
impairment (E-MCI). Front Aging Neurosci. 2013; 5:11. [PubMed: 23554593]
Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders:
neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin
Neuropsychiatry. 2003; 8(4):201–216. [PubMed: 14613048]
Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S, Weiner MW. Alzheimer's Disease
Neuroimaging, Initiative. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative
phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement. 2010; 6(3):265–273.
[PubMed: 20451875]
Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A. Pre-chemotherapy differences in
visuospatial working memory in breast cancer patients compared to controls: an FMRI study.
Front Hum Neurosci. 2011; 5:122. [PubMed: 22053153]
Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A. Prechemotherapy differences in response
inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging
study. J Clin Exp Neuropsychol. 2012; 34(5):543–560. [PubMed: 22380580]
Seigers R, Schagen SB, Van Tellingen O, Dietrich J. Chemotherapy-related cognitive dysfunction:
current animal studies and future directions. Brain Imaging Behav. 2013:1–7. [PubMed:
22660945]
Shen L, Thompson PM, Potkin SG, Bertram L, Farrer LA, Foroud TM, Saykin AJ. for the Alzheimer's
Disease Neuroimaging Initiative. Genetic analysis of quantitative phenotypes in AD and MCI:
imaging, cognition and biomarkers. Brain Imaging Behav. 2013
Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Ganz PA. Altered frontocortical,
cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after
chemotherapy. Breast Cancer Res Treat. 2007; 103(3):303–311. [PubMed: 17009108]
Silverman DH, Mosconi L, Ercoli L, Chen W, Small GW. Positron emission tomography scans
obtained for the evaluation of cognitive dysfunction. Semin Nucl Med. 2008; 38(4):251–261.
[PubMed: 18514081]
Small BJ, Rawson KS, Walsh E, Jim HS, Hughes TF, Iser L, Jacobsen PB. Catechol-O-
methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer
survivors. Cancer. 2011; 117(7):1369–1376. [PubMed: 21425136]
Sporns O. The human connectome: origins and challenges. Neuroimage. 2013a; 80:53–61. [PubMed:
23528922]
Sporns O. Structure and function of complex brain networks. Dialogues Clin Neurosci. 2013b; 15(3):
247–262. [PubMed: 24174898]
Sporns O, Tononi G, Kotter R. The human connectome: A structural description of the human brain.
PLoS Comput Biol. 2005; 1(4):e42. [PubMed: 16201007]
Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological
effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin
Neuropsychol. 2006; 20(1):76–89. [PubMed: 16410227]
Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy
for cancer: report of a workshop. J Clin Oncol. 2004; 22(11):2233–2239. [PubMed: 15169812]
Versace F, Engelmann JM, Jackson EF, Slapin A, Cortese KM, Bevers TB, Schover LR. Brain
responses to erotic and other emotional stimuli in breast cancer survivors with and without distress
about low sexual desire: a preliminary fMRI study. Brain Imaging Behav. 2013:1–10. [PubMed:
22660945]
Vodermaier A. Breast cancer treatment and cognitive function: the current state of evidence,
underlying mechanisms and potential treatments. Womens Health (Lond Engl). 2009; 5(5):503–
516. [PubMed: 19702450]
Saykin et al. Page 15
Brain Imaging Behav. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Walker CH, Drew BA, Antoon JW, Kalueff AV, Beckman BS. Neurocognitive effects of
chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives.
Cancer Invest. 2012; 30(2):135–148. [PubMed: 22250588]
Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose
adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized,
longitudinal trial. Cancer. 2004; 100(11):2292–2299. [PubMed: 15160331]
Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force
recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol.
2011; 12(7):703–708. [PubMed: 21354373]
Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system
cancer and cancer therapy. Neuropsychol Rev. 2008; 18(2):121–131. [PubMed: 18415683]
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Trojanowski JQ. Alzheimer's
Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative: a review of
papers published since its inception. Alzheimers Dement. 2013; 9(5):e111–e194. [PubMed:
23932184]
Saykin et al. Page 16
Brain Imaging Behav. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
